Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert J Desnick

Showing results (1-10 of 207) with videos related to

Pageof 21
Sort By:
Personalized Medicine|May 24, 2018
Genomics and personalized medicine: a perspectiveRobert J Desnick
Expert Opinion on Biological Therapy|July 23, 2004
Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approvalRobert J Desnick
Blood|July 14, 2012
The porphyrias: advances in diagnosis and treatmentManisha Balwani, Robert J Desnick
Molecular Genetics and Metabolism|February 10, 2019
Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapiesMakiko Yasuda, Robert J Desnick
Nephrologie & Therapeutique|March 22, 2007
Fabry disease: clinical spectrum and evidence-based enzyme replacement therapyRobert J Desnick, Maryam Banikazemi
Hematology. American Society of Hematology. Education Program|December 13, 2012
The porphyrias: advances in diagnosis and treatmentManisha Balwani, Robert J Desnick
Molecular Genetics and Metabolism|January 28, 2019
Congenital erythropoietic porphyria: Recent advancesAngelika L Erwin, Robert J Desnick
Molecular Genetics and Metabolism|February 7, 2017
Types A and B Niemann-Pick diseaseEdward H Schuchman, Robert J Desnick
Nature Reviews. Genetics|December 3, 2002
Enzyme replacement and enhancement therapies: lessons from lysosomal disordersRobert J Desnick, Edward H Schuchman
Human Mutation|February 16, 2005
Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatographyJunaid Shabbeer, Misi Robinson, Robert J Desnick
Pageof 21

Showing results (1-10 of 207) with videos related to

Sort By:
Pageof 21
Personalized Medicine|May 24, 2018
Genomics and personalized medicine: a perspectiveRobert J Desnick
Expert Opinion on Biological Therapy|July 23, 2004
Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approvalRobert J Desnick
Blood|July 14, 2012
The porphyrias: advances in diagnosis and treatmentManisha Balwani, Robert J Desnick
Molecular Genetics and Metabolism|February 10, 2019
Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapiesMakiko Yasuda, Robert J Desnick
Nephrologie & Therapeutique|March 22, 2007
Fabry disease: clinical spectrum and evidence-based enzyme replacement therapyRobert J Desnick, Maryam Banikazemi
Hematology. American Society of Hematology. Education Program|December 13, 2012
The porphyrias: advances in diagnosis and treatmentManisha Balwani, Robert J Desnick
Molecular Genetics and Metabolism|January 28, 2019
Congenital erythropoietic porphyria: Recent advancesAngelika L Erwin, Robert J Desnick
Molecular Genetics and Metabolism|February 7, 2017
Types A and B Niemann-Pick diseaseEdward H Schuchman, Robert J Desnick
Nature Reviews. Genetics|December 3, 2002
Enzyme replacement and enhancement therapies: lessons from lysosomal disordersRobert J Desnick, Edward H Schuchman
Human Mutation|February 16, 2005
Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatographyJunaid Shabbeer, Misi Robinson, Robert J Desnick
Pageof 21